Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2012 Jul;57(1):108-15. doi: 10.1016/j.jhep.2012.02.019. Epub 2012 Mar 10.

PMID:
22414764
2.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.

3.

Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.

Beurel E, Blivet-Van Eggelpoël MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C, Desbois-Mouthon C.

Biochem Pharmacol. 2009 Jan 1;77(1):54-65. doi: 10.1016/j.bcp.2008.09.026. Epub 2008 Oct 1.

PMID:
18938143
4.

Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.

Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O.

Int J Cancer. 2006 Dec 1;119(11):2557-66.

5.

GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.

Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Cadoret A, Capeau J, Desbois-Mouthon C.

Int J Oncol. 2005 Jul;27(1):215-22.

PMID:
15942663
6.

GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.

Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C.

Exp Cell Res. 2004 Nov 1;300(2):354-64.

PMID:
15475000
7.

Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.

Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A, Capeau J.

Hepatology. 2002 Dec;36(6):1528-36.

PMID:
12447879
8.

Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation.

Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, Capeau J.

Oncogene. 2001 Jan 11;20(2):252-9.

9.

Insulin-mediated cell proliferation and survival involve inhibition of c-Jun N-terminal kinases through a phosphatidylinositol 3-kinase- and mitogen-activated protein kinase phosphatase-1-dependent pathway.

Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Caron M, Atfi A, Cherqui G, Capeau J.

Endocrinology. 2000 Mar;141(3):922-31.

PMID:
10698166
10.

Insulin differentially regulates SAPKs/JNKs and ERKs in CHO cells overexpressing human insulin receptors.

Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Auclair M, Cherqui G, Capeau J, Caron M.

Biochem Biophys Res Commun. 1998 Feb 24;243(3):765-70.

PMID:
9501008
11.

Major circadian variations of glucose homeostasis in a patient with Rabson-Mendenhall syndrome and primary insulin resistance due to a mutation (Cys284-->Tyr) in the insulin receptor alpha-subunit.

Desbois-Mouthon C, Magré J, Duprey J, Caron M, Blivet-Van Eggelpoel MJ, Daubas C, Gourmelen M, Chevallier B, Rizkalla S, Robert JJ, Capeau J.

Pediatr Res. 1997 Jul;42(1):72-7.

PMID:
9212040
12.

Severe resistance to insulin and insulin-like growth factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor.

Desbois-Mouthon C, Danan C, Amselem S, Blivet-Van Eggelpoel MJ, Sert-Langeron C, Goossens M, Besmond C, Capeau J, Caron M.

Metabolism. 1996 Dec;45(12):1493-500.

PMID:
8969282

Supplemental Content

Loading ...
Support Center